Abstract: A recirculation system for recirculating intestinal content within an intestinal tract of a subject including a recirculation pathway extending from a distal portion of the intestinal tract to a proximal portion of the intestinal tract forming a recirculation loop for recirculating the intestinal content through the proximal portion of the intestinal tract to increase nutrient absorption from the intestinal content. A bypass pathway in fluid communication with the recirculation pathway and configured to divert the intestinal content from the recirculation pathway to continue along the intestinal tract.

Abstract: In one aspect, the present disclosure provides compounds such as those with one or more quaternary ammonium ions joined by one or more aromatic rings. These compounds may have a formula: These compounds may be used in the treatment of a microbial infection such as a bacterial infection including infections of drug resistant strains of bacteria.

Abstract: The present invention generally relates to various dibenzothiophene compounds, processes for preparing these compounds, and uses of these compounds. The present invention also relates to cell imaging agents comprising one or more of the dibenzothiophene compounds and processes for imaging a cell using the compounds. The present invention further relates to methods of producing ground state atomic oxygen.

Abstract: The present disclosure is directed to recombinant mutant Granzyme A molecules that lack enzymatic activity and their use in inhibiting Mycobacterium tuberculosis and treating the related disease states.

Abstract: Disclosed herein are compositions and methods for treating neuropathic pain in a subject in need thereof. Compositions disclosed herein are GPR183 antagonists. The methods include administering to a subject in need thereof a therapeutically effective amount of a GPR183 antagonist.

Abstract: Methods of attenuating an antigenic response in a mammal to one or more Type 1 diabetes related-antigens are provided. The method may result in delaying the onset of decreased pancreatic beta cell function in the mammal and/or at least delaying a reduction in serum C-peptide levels in the mammal The method comprises sublingually administering an effective amount of an insulin-related peptide to the mammal and commonly makes use of a sublingual formulation of an insulin-related peptide that includes an aqueous pharmaceutically acceptable carrier, e.g., an aqueous carrier which comprises at least about 30 vol. % glycerin.

Abstract: In one aspect, the present disclosure provides a compound of the formula: (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.

Abstract: Disclosed are compounds that regulate REV-ERB nuclear receptors that would be useful for treatment of various diseases. These compounds may be used in therapeutic applications such as in the treatment of neurodegenerative disease such as anxiety disorder, autoimmune diseases or disorders, or muscular disorders such as sarcopenia.

Abstract: Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.

Abstract: In one aspect, the present disclosure describes new estrogen receptor-related orphan receptor (EER) inverse agonist compounds. Also described are pharmaceutical formulations, methods of synthesis and uses thereof.

Abstract: The present disclosure is directed to modified hepatitis virus C (HCV) E2 glycoprotein antigens and their use for treating, preventing or reducing the severity or likelihood of HCV infection.

Abstract: The present disclosure is directed to modified plant cells and plants having increased seed number and seed size. Studies identified genes such as ARF8, YDK1, RNA Pol IV, RNA Pol V, DCL3, AGO6, CMT3 and DRM2 as linked to seed characteristics and the inventors therefore propose modulating the expression and/or activity of these target genes in plants as an approach to increase/improve seed production.

Abstract: The present disclosure provides methods of preparing heterostructures of a carbon-based structure and a metal oxide structure. Also provided are heterostructures formed via the methods described herein and devices comprising such heterostructures.

Abstract: The present disclosure relates generally to tissue engineering. Disclosed herein are biomimetic sponges useful for tissue regeneration and methods for making biomimetic sponges.

Abstract: In some aspects, the present disclosure provides compounds of the formula: (I) or (II) wherein the variables are as defined herein. In some embodiments, these compounds may be used to treat cancer or other hyperproliferative diseases, as well as atherosclerosis and coronary artery disease.

Abstract: Disclosed herein are methods for treating neuropathic pain in a subject in need thereof. The methods include: administering to a subject in need thereof a therapeutically effective amount of an antagonist of P2Y14.

Abstract: This invention relates to a novel method of treating solid tumors of the head and neck. More specifically, the invention relates to the use of Momordicine-I (M-I), an extract of bitter melon (Momordica charantia), to treat solid tumors, particularly those of the head and neck as well as the breast. Methods and compositions are disclosed related to administrating Momordicine-I with lipophilic solvents to subjects in need.

Abstract: Disclosed are capped nanoparticles that are effectively trapped within an aqueous gelling solution to produce stable gels and function as a contrast agent for vascular imaging. The contrast agent has good radioopacity, is inexpensive to produce, and is safe to handle. This provides a new method to image the fine vasculature of biological systems.

Abstract: The present disclosure relates to catheters, and more particularly, to urinary catheters that can be used with an endoscope as well as a catheter system comprising a catheter and an endoscope, wherein the endoscope is disposed in the lumen of the catheter. In one instance, a catheter system includes an endoscope and a catheter. The endoscope has an insertion tube sized and shaped to be inserted into a body lumen of a patient. The catheter includes an elongate body having an axis and proximal and distal end portions space apart from one another along the axis. The elongate body is sized and shaped to be received in the body lumen. The elongate body defines a lumen extending between the proximal and distal end portions. The lumen is sized and shaped to receive the insertion tube of the endoscope.

Abstract: Among the various aspects of the present disclosure is the provision of a method of treating a neurodegenerative disease in a subject in need thereof comprising administering a therapeutically effective amount of a TAR DNA-binding protein (TDP-43) modulating agent comprising an RNA oligonucleotide.